Akebia Therapeutics, Inc.

NasdaqCM AKBA

Akebia Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 203,876,369

Akebia Therapeutics, Inc. Shares (Diluted, Weighted) is 203,876,369 for the Trailing 12 Months (TTM) ending September 30, 2024, a 9.63% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Akebia Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 185,970,968, a 1.98% change year over year.
Akebia Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 182,365,700, a 15.05% change year over year.
Akebia Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 158,511,091, a 20.09% change year over year.
Akebia Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2020 was 131,993,735, a 12.08% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqCM: AKBA

Akebia Therapeutics, Inc.

CEO	Mr. John P. Butler MBA
IPO Date	March 20, 2014
Location	United States
Headquarters	245 First Street
Employees	167
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years